Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Revenue: 2021-2025

Historic Revenue for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to $51.3 million.

  • Rhythm Pharmaceuticals' Revenue rose 54.28% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.3 million, marking a year-over-year increase of 54.92%. This contributed to the annual value of $130.1 million for FY2024, which is 68.06% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Revenue stood at $51.3 million for Q3 2025, which was up 5.76% from $48.5 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Revenue peaked at $51.3 million during Q3 2025, and registered a low of $35,000 during Q1 2021.
  • In the last 3 years, Rhythm Pharmaceuticals' Revenue had a median value of $29.1 million in 2024 and averaged $30.9 million.
  • Data for Rhythm Pharmaceuticals' Revenue shows a peak YoY spiked of 4,180.00% (in 2022) over the last 5 years.
  • Over the past 5 years, Rhythm Pharmaceuticals' Revenue (Quarterly) stood at $1.8 million in 2021, then surged by 383.76% to $8.8 million in 2022, then skyrocketed by 175.70% to $24.2 million in 2023, then soared by 72.61% to $41.8 million in 2024, then skyrocketed by 54.28% to $51.3 million in 2025.
  • Its last three reported values are $51.3 million in Q3 2025, $48.5 million for Q2 2025, and $32.7 million during Q1 2025.